# Massimo Aglietta

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/massimo-aglietta/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,814 |
| Field | CAR-T cell therapy research |
| h-index | 76 |
| i10-index | 298 |
| Last Known Institution | Verizon (United States) |
| OpenAlex ID | https://openalex.org/A5056702454 |
| ORCID iD | https://orcid.org/0000-0002-2255-7972 |
| Works | 772 |

## Researcher papers

- [Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer](https://scholariq.org/papers/durable-clinical-benefit-with-nivolumab-plus-ipilimumab-in-dna-mismatch-repair/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)

## Researcher topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Verizon (United States)](https://scholariq.org/institutions/verizon-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.